V. Easton

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Eduard Vrdoljak, Norbert Marschner, Christoph Zielinski et al. · Annals of Oncology · 2016 · 44 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial

Gilles Romieu, Michael Clemens, Rolf Mahlberg et al. · Critical Reviews in Oncology/Hematology · 2007 · 37 citations

Medicine, Oncology, Pharmacology +9

Abstract S3-04: Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer

Grazia Arpino, J-M Ferrero, Juan de la Haba-Rodríguez et al. · Cancer Research · 2017 · 26 citations

Medicine, Oncology, Pharmacology +17

Achieving Full-Dose, On-Schedule Administration of ACE Chemotherapy Every 14 Days for the Treatment of Patients with Extensive Small-Cell Lung Cancer

Robert Pirker, Ernst Ulsperger, Julia Messner et al. · Lung · 2006 · 21 citations

Medicine, Oncology, Chemotherapy +8